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Previous studies have shown that silymarin, a flavonoid antioxidant, possesses a hypolipidemic 
effect. The aim of this study was to evaluate the effect of silymarin on liver phoshpatidate 
phosphohydrolase, total plasma cholesterol, plasma lipoproteins, liver and plasma triglyceride, 
plasma malondialdehyde, and plasma antioxidant in rats fed with high cholesterol diet enriched 
with fat. Male rats were fed by standard pellet diet (group I), standard diet accompanied with 
silymarin (group II), lipogenic diet (containing saturated fat, cholesterol and ethanol) plus 
silymarin (group III), and only lipogenic diet (group IV). On day 60 of the experiment, liver 
phosphatidate phosphohydrolase activity, liver triglyceride, plasma lipids, plasma 
malondialdehyde, and plasma antioxidant levels were measured. Group II showed a significant 
reduction (20%) (p < 0.001) in the liver PAP activity compared to group I. The atherogenic ratio of 
total cholesterol to high density lipoprotein cholesterol, liver triglyceride, plasma total cholesterol, 
and triglyceride levels significantly decreased (p < 0.05) due to silymarin treatment in group III 
compared to group IV. Significant reduction in plasma malondialdehyde (p < 0.05) and significant 
elevation (p < 0.05) in plasma antioxidant power observed in group III compared to group IV. 
These results clearly suggested that silymarin can be effective to reducing liver phosphatidate 
phosphohydrolase activity and liver triglyceride. Furthermore, silymarin had blood lipid-reducing 
and beneficial antioxidant effects in hyperlipidemic diets.  
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 Silymarin (SM), extracted mainly from the 
seeds of milk thistle (Silybum marianum L.), is 
usually composed of a mixture of six major 
isomeric flavonolignans (silychristin, 
silydianin, silybin A, silybin B, isosilybin A, and 
isosilybin B) (Wen et al., 2008). Extracts of 
milk thistle have been used for centuries as 
herbal remedies for liver and biliary tract 
diseases (Gazák et al., 2007; Basiglio et al., 
2009). Previous animal studies and clinical 
trials have shown the safety of SM in humans 
and animals (Dixit et al. 2007).  
Phosphatidate phosphohydrolase (PAP, 
EC 3.1.3.4) is a major enzyme in controlling 
the synthesis of triacylglycerol and 
glycerophospholipids (Carman and Han, 
2006). PAP catalyzes the dephosphorylation 
of phosphatidic acid to yield inorganic 
phosphate (Pi) and 1 ,2 diacylglycerol. Then, 
the diacylglycerol serves as a precursor for 
the biosynthesis of major glycerol-
phospholipids in animal cells (Fleming and 
Yeaman, 1995; Carman and Han, 2006). 
Additionally, triglyceride (TG) plays as an 
important storage molecule in living 
organisms and allows organisms to survive 
periods of food deprivation. In human 
diseases, the control of TG storage is very 
important because both excessive and 
inadequate fat storage are accompanied with 
dyslipidemia, insulin resistance, and diabetes 
(Petersen and Shulman, 2006; Reue and 
Phan, 2006). In rat hepatocytes, two different 
types of PAP have been reported based on N-
ethylmaleimide (NEM) sensitivity (Carman 
and Han, 2006; Heidarian and Haghighi, 
2008). The NEM-sensitive form (PAP1) is a 
regulatory enzyme in TG and phospholipids 
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biosynthesis. PAP1 is located in cytosol and 
microsomal fractions. PAP1 requires Mg
2+
 for 
its activity (Carman and Han, 2006). The 
second form is PAP2 and it does not require 
Mg
2+
 for its activity. PAP2 is present in plasma 
membrane which is primarily involved in lipid 
signaling pathways by modulating the second 
messengers of diacylglycerol and 
phosphatidic acid (Carman and Han, 2006). 
Hypercholesterolemia is considered a risk 
factor for coronary heart diseases.  Previous 
studies have suggested that polyphenolic 
compounds found in fruits, vegetables, and 
plants reduce coronary heart disease mortality 
(Maron, 2004). Milk thistle (Silybum marianum 
L.) is a plant rich in phenolic compounds. 
There is positive evidence for hypolipidemic 
effects of SM (Metwally et al. 2009). The 
consumption of SM leads to the reduction of 
cholesterol in liver and plasma very low 
density lipoprotein (VLDL). Also, SM 
decreases VLDL cholesterol / HDL (high 
density lipoprotein) cholesterol ratio in rats fed 
on high-cholesterol diet or on high-sucrose 
diet. Nevertheless, the previous studies on 
SM focus less on enzymes involving in 
triglyceride metabolism, especially PAP 
enzyme, in details. Therefore, the aim of this 
study was to determine the effects of dietary 
supplementation with SM on the liver PAP, 
liver triglyceride content, plasma lipids, 
plasma antioxidant capacity, and plasma 
malondialdehyde (MDA) levels in rats fed with 
high cholesterol diet enriched with fat. 
 
MATERIALS AND METHODS  
Chemicals 
Phosphatidic acid (sodium salt), 
dithiothreitol (DTT), 2,4,6-tripyridyl-s-triazine 
(TPTZ), silymarin, and phenylmethylsulfunyl 
fluoride (PMSF) were purchased from Sigma 
(Sigma Chemical Co., USA). Bovine serum 
albumin, Tris–HCl, ethylenediaminetetra 
acetic acid (EDTA), ethyleneglycol-bis (beta-
aminoethyl ether)-N,N,N',N'-tetraacetic acid 
(EGTA), sucrose, 2-thiobarbituric acid (TBA), 
and ferric chloride (FeCl3.6H2O) were 
provided from Merck (Germany). All other 
chemicals used were of analytical grade. 
  
Animals and experimental design 
Male Wistar albino rats (150-200 g) were 
maintained at approximately 22 
°
C with a 12 h 
light/12 h darkness cycle, and had free access 
to food and tap water. Animals were randomly 
divided into 4 experimental groups (n = 6/ 
group) as below: 
Group I, normal control rats which 
received standard pellet chow (Pars dam, 
Iran). This group received 0.5 ml distillated 
water by gavage to produce equal injection 
shock similar to other groups. 
Group II, animal rats fed with a standard 
pellet chow plus 25mg/kg body weight /day 
SM dissolved in 1% arabic gum (Metwally et 
al., 2009) for 45 days.  
Groups III and IV, the rats fed with a 
lipogenic diet containing standard pellet chow 
supplemented with 0.5% cholic acid, 20% 
saturated fat, and 2% cholesterol for two wk to 
produce hyperlipidemia. Additionally, group III 
and group IV drank water containing 3% 
ethanol (Yanardag et al., 2005). After 2 weeks 
of lipogenic diet feeding, group III orally 
received 25mg/kg body weight /day SM 
suspended in 1% arabic gum accompanied 
with lipogenic regime for 45 days. The rats in 
group IV were maintained on lipogenic diet 
(hyperlipidemic control group) throughout the 
experiment and received 0.5 ml distillated 
water by gavage to produce equal injection 
shock similar to other groups. On d 60 of the 
experiment, fasted animals were anesthetized 
with chloroform and their blood samples were 
collected in test tubes containing EDTA 
through cardiac puncture. All plasma 
specimens were separated by low speed 
centrifugation (2000g) for 10 min and were 
stored at -80 °C until they were analyzed. All 
animal procedures were performed with 
regard to Iranian animal ethics society and 
local university rules.  
 
Analytical procedures 
Total cholesterol (TC), plasma TG, high 
density lipoprotein cholesterol (HDL-C), and 
low density lipoprotein cholesterol (LDL-C) 
levels were determined by enzymatic method 
(Pars Azmun kit, Iran) using atuoanalyzer (BT 
3000, France). Very low density lipoprotein 
cholesterol (VLDL-C) was calculated with 
Fridewald formula (1972). Liver triglyceride 
was extracted from liver tissue using a 
chloroform–methanol mixture by Folch-altered 
method invented by Norman (1969). 
 
Preparation of rat liver homogenate 
The liver of each rat was perfused 
through the inferior vena cava with ice-cold 
saline (0.9%) to remove blood and inorganic 
phosphate from it in order to assess the liver 
PAP activity and the liver triglyceride. A 
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portion of perfused liver was homogenized in 
4 volumes of ice-cold buffer (pH 7.4) 
containing 50 mM Tris–HCl, 0.25 M sucrose, 
1 mM PMSF, and 0.1 mM EDTA by 
homogenizer (Heidolph, Silentcrusher M 
model, Germany) at 8000 rpm at 4 °C for 5 
min (Heidarian et al., 2011). The homogenate 
was centrifuged at 4500 rpm at 4 °C for 10 
min and then, the supernatant was kept for 
the enzyme assay.   
 
Determination of liver PAP activity 
PAP activity was measured by the 
method of Yanagita et al. (2003) with slight 
modification. In brief, PAP activity was 
assayed in the assay buffer containing 50 mM 
Tris–HCl (pH 7.4), 1 mM of phosphatidate, 
1.25 mM magnesium chloride, and 50 to 100 
μg of liver enzyme solution in a final assay 
volume of 0.2 mL. The mixture was incubated 
for 15 min at 37°C. The reaction was stopped 
by the addition of 0.8 mL of a solution 
containing 0.13% sodium dodecyl sulfate, 
1.25% ascorbic acid, 0.32% ammonium 
molybdate-4H2O, and 0.75 N H2SO4. Then, 
the liberated inorganic phosphate was 
measured. The phosphomolybdate color was 
developed at 45°C for 20 min, and the 
absorbance was measured at 820 nm. Non-
enzymatic phosphate release was determined 
by inactivating the enzymes through boiling 
for 1 min without substrate. The enzyme 
activity was expressed as phosphate 
nanomoles in one minute per milligram of 
protein. All assays were linear in relation to 
the incubation time and the protein 
concentrations used in them. Protein 
concentrations were determined by the 
method of Bradford (1976) calibrated with 
bovine serum albumin. 
 
Measurement of plasma malondialdehyde 
(MDA) 
Lipid peroxidation in the plasma was 
estimated by the calculation of MDA levels 
using thiobarbituric acid according to the 
method of Ohkawa et al. (1979). The plasma 
samples were incubated for 1 hour at 95°C 
with thiobarbituric acid. After the reaction of 
MDA with thiobarbituric acid, the reaction 
color product was measured 
spectrophotometrically at 532 nm using a 
Unico 1200 UV–visible spectrophotometer 
(USA). The measurements were done in 
duplicates and the results were expressed in 
μM. MDA standards were prepared from 
1,1,3,3-tetraethoxypropane (TEP). 
 
Ferric reducing/antioxidant power (FRAP) 
assay  
The antioxidant capacity of each sample 
was measured according to the procedure 
described by Benzie and Strain (1996). In this 
method, the complex between Fe
2+
 and TPTZ 
gives a blue color with absorbance at 593 nm. 
FeSO4.7H2O was used as a standard of 
FRAP assay at a concentration range 
between 100 to 1000 μM.  
 
Statistical analysis 
Results are expressed as mean ± S.D. 
The data were analyzed by SPSS software 
(version 11.5). One-way analysis of variance 
(ANOVA) was carried out, and the statistical 
comparisons among the groups were 
performed with Tukey’s test. Differences were 
considered significant at capacity < 0.05 level. 
 
RESULTS  
Effect of SM on the liver triglyceride, 
cholesterol, and PAP activity 
Table 1 demonstrates the effect of SM on 
liver triglyceride, cholesterol, and PAP activity 
in experimental groups. In group IV, high 
cholesterol diet caused significant (p < 0.001) 
accumulation of cholesterol and TG in the 
liver in comparison with groups I and III. In 
group II, SM significantly decreased (57%) (p 
= 0.001) the content of TG in the liver 
compared to group I. No significant change 
was observed in liver cholesterol between 
groups I and II (p > 0.05). Also, in group III 
SM caused almost threefold decrease (66%) 
(p < 0.001)  in the content of liver TG and led 
to a noticeable reduction (41%) (p < 0.001) of 
hepatic cholesterol content compared to 
group IV. 
 Group II showed a significant reduction 
(20%) (p < 0.001) in the liver PAP activity 
compared to group I. No significant change (p 
> 0.05) was observed in liver PAP activity of 
group IV compared to groups II and III. Also, 
there was a noticeable reduction (p < 0.05) in 
PAP activity between groups III and IV 
compared to group I.  
 
Effect of SM on plasma lipoproteins  
Table 2 shows the values of lipid 
parameters found after feeding rats on 
lipogenic diet in experimental groups. The 
levels of plasma TG, TC, VLDL-C, and LDL-C 
in group IV (consuming lipogenic diet)  
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Table 1: Effect of SM on the liver TG, cholesterol, and PAP activity in experimental groups. 
 
Groups PAP activity  
(nmolPi/min/mg  
protein) 
Liver triglyceride 
(mg/g tissue) 
Liver cholesterol 
(mg/g tissue) 
Group I ( control) 14.24 ± 0.61 4.32 ± 0.41 1.58 ± 0.21 
Group II 11.38 ± 0.46* 1.82 ± 0.35*
#
 1.26 ± 0.24
#
 
Group III 10.92 ± 0.68* 5.48 ± 0.65
#
 4.84 ± 0.70*
#
 
Group IV 10.46 ± 0.83* 16.35 ± 1.74* 8.20 ± 0.92* 
 
The data were expressed as mean  S.D.; n = 6 in each group. Normal control (I); control 
supplemented with silymarin (II); hyperlipidemic rats treated with silymarin (III); hyperlipidemic 
rats without treatment (IV) groups.
 
* p < 0.05 compared with the corresponding value for group I (normal control animals). 
#
 p < 0.001 compared with the corresponding value for group IV (hyperlipidemic animals). 
 
 
Table 2:  Effect of SM on TC, TG, LDL-C, HDL-C, VLDL-C levels and atherogenic index in 
rats fed by high cholesterol diet.  
 
Parameters Group I Group II Group III Group IV 
TC (mg/dl) 58.66 ± 4.88 51.33 ± 5.25 79.97 ± 4.75** 121.16 ± 9.55
 #
 
TG (mg/dl) 54.37 ± 7.23 43.01 ± 3.69* 66.08 ± 5.78** 91.83 ± 7.96
#
 
HDL-C (mg/dl) 58.50 ± 5.01 48.22 ± 4.95* 53.23 ± 3.68** 40.84 ± 4.72
#
 
LDL-C (mg/dl) 18.55 ± 2.05 13.05 ± 1.51* 34.27 ± 3.08** 47.30 ± 4.09
#
 
VLDL-C (mg/dl) 10.58 ± 1.61 8.81 ± 0.98 13.13 ± 1.15** 18.36 ± 1.58
#
 
TC/HDL-C 
(units) 
1.03 ± 0.13 1.04 ± 0.11 1.51 ± 0.13** 2.67 ± 0.22
#
 
LDL/HDL-C 
(units) 
0.31 ± 0.20 0.26 ± 0.27 0.67 ± 0.11** 1.16 ± 0.13
#
 
 
The data are expressed as mean ± S.D.; n = 6 in each group. Normal control (I); control 
supplemented with SM (II); hyperlipidemic rats treated with SM (III); hyperlipidemic rats without 
treatment (IV) groups.
 
* p < 0.05 compared with the corresponding value for group I (normal control animals). 
**p < 0.001 compared with the corresponding value for group IV (lipogenic regime). 
# p < 0.001 compared with the corresponding value for groups I and II.  
 
 
significantly increased (p < 0.001) compared 
to other groups. The level of HDL-cholesterol 
significantly increased (p < 0.001) in group III 
compared to group IV. In group III, the plasma 
level of cholesterol significantly decreased (p 
< 0.001) in comparison with group IV. The 
plasma level of TG in groups II and III (groups 
supplemented with SM) was significantly 
lower (p < 0.05) than groups I and IV, 
respectively. In group II the plasma levels of 
HDL-C and LDL-C significantly reduced (p < 
0.05) compared to group I. VLDL-C was 
declined in group II in contrast with group I 
(control group) but it was not significant (p > 
0.05). The level of VLDL- C in group III 
showed a remarkable reduction (p < 0.001) 
compared with group IV. Group IV showed a 
noticeable (p < 0.001) elevation in 
atherogenic index of plasma (TC/HDL-C and 
LDL/ HDL-C) with respect to other groups. A 
significant reduction (p < 0.001) was observed 
for atherogenic index of plasma in group III 
compared with group IV. No significant 
change was seen for atherogenic index of 
plasma in group II compared with group I (p > 
0.05). 
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Effects of SM on the plasma level of MDA 
Rats fed on lipogenic diet without tratment 
(group IV) showed a significant increase (p < 
0.001) in plasma MDA compared to group I 
fed on normal diet (Fig. 1). In group III 
(hyperlipidemic rats treated with SM) the 
consumption of SM led to an important 
reduction (p < 0.05) of plasma MDA 
compared to group IV. No significant change 
was observed in plasma MDA level between 
groups I and II (p > 0.05). 
 
 
 
Figure 1. Plasma malondialdehyde level in 
normal diet (I); normal diet supplemented 
with silymarin (II); hyperlipidemic rats 
treated with silymarin (III); hyperlipidemic 
rats without treatment (IV) groups. The 
data are expressed as mean ± S.D, n = 6 in 
each group.  
# p < 0.001 compared with the corresponding 
value for normal control animals.  
*p < 0.001 compared with the corresponding 
value for hyperlipidemic rats without 
treatment. 
 
Effect of SM on the plasma level of 
antioxidant power 
Fig. 2 shows, the plasma level antioxidant 
power (FRAP) in each experimental animal 
group. In groups II and III (rats administrated 
with SM) the plasma antioxidant power 
significantly increased (p < 0.001) as 
compared to groups I and IV, respectively. 
There was a noticeable reduction (p < 0.001) 
in plasma level antioxidant power in group IV 
(hyperlipidemic animals) in comparison to 
group I. No significant change was observed 
in plasma level antioxidant power between 
groups II and III (p > 0.05). 
 
 
Figure 2. Plasma level antioxidant power 
(FRAP) in normal diet (I); normal diet 
supplemented with silymarin (II); 
hyperlipidemic rats treated with silymarin 
(III); hyperlipidemic rats without treatment 
(IV) groups. The data are expressed as 
mean ± S.D, n = 6 in each group.  
# p < 0.001 compared with the corresponding 
value for normal control animals.  
*p < 0.001 compared with the corresponding 
value for hyperlipidemic rats without 
treatment. 
 
DISCUSSION 
Elevated serum lipid and lipoprotein 
levels, especially hypercholesterolemia, 
increase the risk of cardiovascular diseases, 
fatty liver, carcinogenesis, and atherosclerosis 
(Gould et al. 2007). Nowadays, many new 
synthetic oral antihyperlipidemic drugs are 
available but they have adverse side effects 
such as myopathy, increase in hepatic 
aminotransferases, and rhabdomyolysis 
condition (Anfossi et al., 2004). In recent 
years, many studies have been conducted on 
using of pure flavonoids owing to their 
biological properties for treating many 
important common diseases especially 
obesity and its complications (Šobolová et al., 
2006; Andersen et al., 2010). In previous 
studies, SM is introduced as lipid-lowering 
therapeutic agent (Šobolová et al., 2006; 
Metwally et al. 2009) but, to the best of our 
knowledge, there has been no study 
investigating the effect of SM on PAP in 
hypercholesterolemic animals or humans. In 
this study, the ingestion of the lipogenic diet 
led to elevation of the plasma levels of 
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cholesterol, VLDL, LDL, and liver TG and 
cholesterol in group IV(hyperlipidemic 
animals) whereas, in groups II and III (rats 
treated with SM) the plasma levels of 
cholesterol, VLDL, LDL, liver TG, and liver 
cholesterol decreased compared to groups I 
and IV, respectively. The same results 
reported by other investigators (Škottová et 
al., 2003; Turley, 2004; Metwally et al. 2009). 
It has been demonstrated that the 
consumption of diet rich in fatty acids and 
cholesterol leads to an accumulation of 
cholesterol and TG in nonadipose tissues 
such as the liver. Also, cholesterol represses 
the activity of HMG-CoA reductase and blocks 
cholesterol synthesis in the liver. In addition, 
cholesterol leads to elevated hepatic VLDL 
secretion and suppression of the synthesis 
and activity of LDL receptors. Therefore, 
VLDL remnants and LDL circulate for 
prolonged period and this cause a rise in total 
plasma cholesterol (Goldstein and Brown, 
1984; Turley, 2004). Moreover, previous 
studies have shown that the polyphenolic 
fraction of SM positively modifies lipoprotein 
profile in plasma. In addition, SM counteracts 
the development of fatty liver in rats fed on 
lipogenic diet (Škottová et al. 2003). 
Additionally, it has been reported that feeding 
rats by SM leads to significant decrease of 
total plasma and liver cholesterol through the 
inhibition of intestinal cholesterol absorption 
(Škottová et al., 2003; Šobolová et al. 2006). 
Therefore, in this study the significant 
reduction of LDL and VLDL cholesterol after 
SM treatment could be due to a decrease in 
VLDL formation and secretion from the liver. 
Moreover, the SM supplementation with 
lipogenic diet caused reduction of plasma 
LDL-cholesterol and atherogenic index. These 
results suggest that SM can be applicable to 
reduce the coronary heart diseases in 
hyperlipidemic conditions. Additionally, in this 
research the liver cholesterol reduction was, 
at least in part, through SM inhibition of 
intestinal cholesterol absorption which 
previously reported (Škottová et al. 2003; 
Šobolová et al. 2006). In our study, rats fed on 
high cholesterol diet had lower HDL 
cholesterol concentration than the groups fed 
by standard laboratory diet. The reduction of 
HDL cholesterol in several species has been 
reported following cholesterol feeding (Sorci-
Thomas et al. 1989; Rudel, 1997). In this 
study, the increase in plasma level of HDL 
fraction in treated hyperlipidemic rats (group 
III) was another positive change observed 
after SM treatment. Studies in nonhuman 
primates indicate that cholesterol-enriched 
diets result in the reduction of plasma HDL 
concentration through accelerated apoA-I 
clearance from the plasma (Sorci-Thomas et 
al. 1989). Also, there is evidence that plant 
polyphenolics can increase the liver secretion 
of apoA-I (Theriault et al. 2000). Therefore, in 
this study, the elevation of HDL fraction in rats 
treated with SM can occur due to SM 
polyphenolic property on apoA-I metabolism.  
The published works hitherto do not 
assess the effect of SM on PAP activity in 
hyperlipidemic rats. Also, there is no reported 
data on lipid-lowering mechanism(s) of SM on 
PAP enzyme. Recently, the effect of garlic 
reported on the liver PAP activity in normal 
and hyperlipidemic rats (Heidarian et al. 
2011). The consumption of garlic, as a 
medicinal plant, led to the reduction of liver 
PAP activity and liver TG content. In present 
work, our data have shown that the SM 
supplementation results in higher reduction of 
PAP activity in group II than group I (control). 
Therefore, reduction in liver PAP activity, 
owing to SM, subsequently led to declining of 
plasma and liver TG which is useful to reduce 
the risk of cardiovascular diseases, fatty liver, 
and atherosclerosis.  On the other hand, in 
animals fed with high cholesterol diet (groups 
III and IV) PAP activity decreased compared 
to control group whereas, the liver TG and 
cholesterol concentrations increased in this 
groups (Table 1). It has been reported that 
excessive intake of fatty acids caused 
accumulation of TG in many tissues, 
especially in fat tissue and non-adipose 
tissues such as liver (van Herpen and 
Schrauwen-Hinderling, 2008). In addition, it 
was demonstrated that fatty acid esters lead 
to the inactivation of PAP. Fatty acids and 
their acyl-CoA esters regulate PAP by a 
negative allosteric interaction. The formation 
of PAP fatty acid (or acyl-CoA esters) 
complex causes the inactivation of PAP 
(Elabbadi et al. 2005).  Therefore, in this 
study, the decrease of PAP activity (Table 1) 
in groups fed with high cholesterol diet 
enriched with fat (groups III and IV) seems to 
be caused by the accumulation of TG, fatty 
acids or acyl-CoA esters in the liver. 
Nevertheless, the reduction of PAP activity in 
groups fed with high lipid regime (Groups III 
and IV) can probably act, at least in part, as a 
defense mechanism of liver for reducing the 
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production of endogenous liver TG. Therefore, 
serum and liver TG will decrease and 
possibly, reduce the risk of liver damage 
especially fatty liver and cirrhosis. Besides, 
the elevated liver TG and cholesterol in group 
III significantly reduced as opposed to group 
IV (Table 1) through supplementation with 
SM. Therefore, the SM can reduce the liver 
content of TG and cholesterol. Overall, SM 
can be useful in lowering and treating fatty 
liver in hyperlipidemic regime. 
In this research, we did not assess the 
effects of SM on the other enzymes involving 
in the lipid metabolism, especially glucose-6-
phosphate dehydrogenase (G6PDH) and 
malic enzyme. These enzymes produce 
NADPH employed for fatty acid and 
cholesterol biosyntheses. We propose that 
future studies can focus on other possible 
mechanisms of the triglyceride-lowering action 
of the SM or the bioactive components of milk 
thistle on the mentioned enzymes. 
Oxidative stress of plasma lipoproteins, 
erythrocytes, and several tissues such as 
liver, heart and aorta have been demonstrated 
in experimental animals fed on high 
cholesterol diet (Küskü-Kiraz   et al. 2010). 
Also, increased oxidative stress parameters 
have been reported in hypercholesterolemic 
individuals (Ondrejovičová et al. 2010). The 
level of MDA is considered as a biomarker of 
lipid peroxidation. It has been demonstrated 
that the phenolic content of plant materials is 
related to their antioxidant activity (Juan and 
Chou, 2009).  SM is well-known for its potent 
antioxidant and chemoprotectant effects on 
liver through its flavonolignans. It is easily 
absorbed from gastrointestinal tract and has 
strong free radical scavenging properties. 
Also, silymarin increases the activity of the 
antioxidant enzymes, such as superoxide 
dismutase (SOD), catalase, and inhibits lipid 
peroxidation (Post-White et al., 2007). In this 
research, SM supplementation caused 
significant decreases in plasma lipid 
peroxidation together with an increase in 
plasma antioxidant power (Figs. 1and 2). 
There are data suggesting the ability of 
phenolics to modulate and positively affect 
lipoprotein metabolism (Škottová et al. 2003). 
The ability of SM to protect a cell membrane 
against toxic materials is attributed mainly to 
its antioxidant potential to eliminate reactive 
oxygen species (ROS), chain-breaking activity  
and a reduction in ROS production (Gazák et 
al. 2007; Basiglio et al. 2009). Therefore, on 
the basis of our results, SM can probably play, 
at least in part, an anti-atherogenic role by 
lowering lipids oxidation in hyperlipidemic 
diets. 
 
CONCLUSIONS 
These results clearly suggested that 
silymarin can be effective in reducing liver 
phosphatidate phosphohydrolase activity and 
liver triglyceride. Also, silymarin has blood 
lipid-reducing, anti- fatty liver, and antioxidant 
effects in hyperlipidemic regimes, probably 
due to its polyphenolic properties. 
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